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Inhibition of Melanogenesis for Melanoma Therapy? 
To the Editor: 
Metastatic melanotic melanoma causes more deaths than any other 
skin tumor [1]. T his is primarily due to the inefficacy of conven-
tional chemotherapy and radiotherapy . Because intermediates of 
melanogenesis are melanocytotoxic [2], it has been proposed to 
destroy melanotic melanoma cell s by upregulation of melanogene-
sis and an increased supply of amino acid precursors (L-tyrosine, 
L-DOPA) or false precursors to melanin [3] . Though this strategy 
worked in il'l lIitro systems [2], we are not aware of any patient cured 
by such a protocol [4]. On the contrary, L-DOPA therapy in pa-
tients with Parkinson's disease is considered by some authors to be a 
risk factor for developing melanoma [5] . 
Almost 30 years ago, Demopoulos et al. [6,7] showed that inhibi-
tion of melanogenesis by restriction ofL-phenylalanine and L-tyro-
sine in the diet, or inhibition of tyrosinase, can slow if not reverse 
the progression of melanotic melanoma in humans and inhibit their 
growth in mice -observations later confirmed in rodent melanoma 
systems [8,9]. Thus, the inllillo situation appears to be the opposite of 
i ll vitro conditions: although dietary restriction of these amino acids 
may inhibit melanoma growth ill lI illO, increased supply of precur-
sors to melanin in vitro results in profound melanocytotoxicity [2]. 
This raises the question of what factors limit the effectiveness of 
melanocytotoxicity by melanogenesis i/1 "illo. 
The answer may lie in the role of L-DOPA, which is present in 
high concentration in melanotic melanomas [10], and can be re-
leased by melanoma cells together with other intermediates of mel-
anogenesis [11] . DOPA and its 3,4-dihydroxy analogs can inhibit 
phytohemagglutinin-stimulated DNA synthesis in lymphocytes 
from melanoma patients [12] and can dramaticall y inhibit lipopoly-
saccharides and concanavalin A- induced proliferation of human 
and mouse lymphocytes [13] . 
Melanogenically active cells may, therefore, be capable of inhib-
iting the local immune attack against malignant cells as well as the 
system.ic immune response via the production/release of L-DOPA 
and its metabolites. Intermediates of melanogenesis are detectable in 
serum of patients with melanotic melanoma [14]. T his may coun-
teract the efficacy of immunotherapy and may magnify the immu-
nosuppression present as a consequence of chemo- and radiother-
apy. Therefore, we support the concept of including strict dietary 
restriction of L-tyrosine and L-phenylalanine in melanoma therapy 
[6,7]' particularly when chemo- or immunotherapy are employed. 
Furthermore, because tyrosinase (the enzyme that oxidates tyros ine 
to DOPA and DOPA to DOPAquinone) is liberated after the de-
struction of melanotic melanoma cells [2], we propose to test 
w hether immunization with purified tyrosinase and treatment with 
inhibitors of tyrosinase is beneficial as an adjuvant therapy in the 
treatment of melanotic melanoma. 
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T-Cell Receptor Vp-Family Usage in Cutaneous Malignancies 
To the Editor: 
T-cell receptor (TCR) gene rearrangements constitute a unique 
marker of clonal ity in cutaneous lymphoid infiltrates. Consc-
quently, they are of particular value for the diagnosis and follow-up 
of patients w ith T-cell neoplasms [1 ,2]. Scvera l groups have applied 
polymerase chain reaction (PCR) - based techniques for the qualita-
tive and semiquantitative analysis of the TCR variable region usage 
[3- 6). 
In their article "T Cell Receptor V p-Family Usage in Primary 
Cutaneous and Primary N odal T-cell Non-Hodgkin's Lympho-
mas," Prcesman et al [6] report the amplification and semiquantita-
tive evaluation of TCR P rearrangcments in eight patients with 
mycosis fungoidcs (MF) or nodal non-Hodgkin'S lymphoma 
(NNHL) . For this purpose they amplified cDNA preparations from 
the respective lesions using a panel of 20 VfJ-region specific PCR 
primers. The PCR products were then separated on agarose gels 
stained with ethidium bromide, visualized under ultraviolet light 
and quantified by eyesight. Different levels of expression of TCR 
VfJ-regions were described by ass ignment to five groups ranging 
from non-detectable PCR product to PCR product signal as strong 
as the positive control. Furthermore, immunohistologic studies and 
gene rearrangement analysis by Southern blotting were performed. 
A varying intensity of the PCR product bands observed among 
hea lthy volunteers led to the conclusion that the primer set em-
ployed was "suitable to detect all 20 [V fJ-] farnilies." From the fact 
that three T-cell lines each expressed only one or two Vp-families, 
they deduced that the PCR primers "showed ... no cross-reacti-
vity" among the variolls V fJ regions. Moreover, the expression of 
one or two Vp-families in three advanced cases of MF and a "poly-
clonal" pattern in an early MF case was reported. The results gave 
